Publicaciones en colaboración con investigadores/as de Dana–Farber Cancer Institute (7)

2018

  1. ERþ Breast cancers resistant to prolonged neoadjuvant letrozole exhibit an e2f4 transcriptional program sensitive to cdk4/6 inhibitors

    Clinical Cancer Research, Vol. 24, Núm. 11, pp. 2517-2529

  2. Multicenter phase II study of lurbinectedin in BRCAMutated and unselected metastatic advanced breast cancer and biomarker assessment substudy

    Journal of Clinical Oncology, Vol. 36, Núm. 31, pp. 3134-3143

2016

  1. Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: Patient-reported outcomes in the suppression of ovarian function trial

    Journal of Clinical Oncology, Vol. 34, Núm. 14, pp. 1601-1610

  2. Twelve-month estrogen levels in premenopausal women with hormone receptor-positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen in the suppression of ovarian function trial (SOFT): The SOFT-EST substudy

    Journal of Clinical Oncology, Vol. 34, Núm. 14, pp. 1584-1593

2014

  1. Predicting response and survival in chemotherapy-treated triple-negative breast cancer

    British Journal of Cancer, Vol. 111, Núm. 8, pp. 1532-1541

2010

  1. The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: The experience of the BIG 02-98 trial

    Breast Cancer Research and Treatment, Vol. 119, Núm. 1, pp. 145-153

2008

  1. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial

    Annals of Oncology, Vol. 19, Núm. 6, pp. 1090-1096